LUND, Sweden, March 18, 2021 /PRNewswire/ --
Alligator Bioscience (Nasdaq Stockholm: ATORX) today
announced that the Annual Report for 2020 has been published. The
Annual Report is attached as a PDF and is available on the
company's
website, https://alligatorbioscience.se/en/investors/financial-reports/
For further information, please contact:
Per Norlén, CEO
E-mail: per.norlen@alligatorbioscience.com
Phone: +46 46 540 82 00
Marie Svensson, CFO
E-mail: marie.svensson@alligatorbioscience.com
Phone: +46 46 540 82 03
The information was submitted for publication, through the
agency of the contact person set out above, at 4:30 p.m. CET on March 18,
2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc. In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-PrimeTM. Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit
www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-publishes-annual-report-for-2020,c3309387
The following files are available for download:
|
https://mb.cision.com/Main/12681/3309387/1389090.pdf
|
Alligator Bioscience
Annual Report 2020
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-publishes-annual-report-for-2020-301250382.html
SOURCE Alligator Bioscience